Costco teams up with Novo Nordisk to sell Ozempic and Wegovy at $499, making popular weight-loss drugs more affordable for members.
Tags: Novo Nordisk
Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity
Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.
Novo Nordisk Responds to Eli Lilly Rivalry with Major Drug Price Reductions
Novo Nordisk will cut Wegovy and Ozempic prices by up to 50% in 2027 to compete with Eli Lilly and expand patient access.
Wegovy Pill Now Available in US, Offering New Oral Option for Obesity Treatment
Novo Nordisk's Wegovy pill is now available in the U.S., offering a convenient oral option for weight loss.
Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls
Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.
Latest News
Novo Nordisk will cut 9,000 jobs to refocus on obesity and diabetes treatments amid rising competition from rivals like Eli Lilly.
Novo Nordisk's Wegovy shows a 57% lower risk of heart attack and stroke in new study, boosting its edge over Eli Lilly.
Novo Nordisk ends partnership with Hims & Hers over concerns about unsafe Wegovy sales and FDA violations.
Novo Nordisk's CagriSema helps patients lose over 20% body weight in late-stage obesity trial.
Novo Nordisk partners with Septerna in a $2.2 billion deal to develop oral treatments for obesity, type 2 diabetes, and other metabolic diseases.
Novo Nordisk reassures investors with strong growth forecasts, rising GLP-1 drug demand, and promising new treatments despite market challenges.
Novo Nordisk launches Wegovy in China, offering an effective weight-loss solution for about 180 million obese Chinese population, though not covered by insurance.
A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.
Shares of pharmaceutical companies Novo Nordisk and Eli Lilly slid after Roche announced results from a promising early-stage trial for its proposed obesity drug.
